報價延遲最少15分鐘:2025/05/30 15:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
58.07 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.70/5.13
|
|
企業價值
11.82B
|
| 資產負債 |
|
每股賬面淨值
30.21
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
2.85B
|
|
每股收益
12.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 15:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline oftreatments in development. |